Publication at First Faculty of Medicine |
2013
Abstract
The treatment of type 2 diabetes mellitus by dipetidyl-peptidase 4 inhibitors is now being increasingly used in the early stages of this disease owing to its good efficacy, negligible side effects and potential cardio- and beta-cell-protective effects. Vildagliptin is a representative of this therapeutic group with proven efficacy and safety in a broad range of patients with type 2 diabetes.
The aim of this paper is to review current experience and novel data concerning the use of vildagliptin in the treatment of diabetes including broaden indications of its use. We will also focus on the recently published studies exploring the antidiabetic efficacy and modulation of glycemic variability by vildagliptin treatment.